Pieris Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Fair Value Measurements - Schedule of Fair Value Measurement Key Assumptions (Details)	Dec. 31, 2024 yr	Dec. 31, 2023 yr	Nov. 30, 2023
Discount rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative, assumption	0.20	0.25	0.22
Probability rate of achieving FDA approval of a product
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative, assumption	0.566	0.50
Expected term to FDA regulatory approval of a product
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative, assumption	2.5	3.5